Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

被引：0

作者：

Michele Kohli

Donna Lawrence

Jennifer Haig

Andrea Anonychuk

Nadia Demarteau

机构：

[1] OptumInsight,

[2] Health Economics and Outcomes Research,undefined

[3] GlaxoSmithKline Biologicals,undefined

[4] Global Vaccines Development,undefined

来源：

BMC Public Health | / 12卷

关键词：

Human papillomavirus; Cervical cancer; Vaccine; Cost-effectiveness; Markov model; Canada;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®) A Review of its Use in the Prevention of Premalignant Cervical Lesions and Cervical Cancer Causally Related to Certain Oncogenic HPV Types
McKeage, Kate
Romanowski, Barbara
DRUGS, 2011, 71 (04) : 465 - 488
[42] AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): A review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types
McKeage K.
Romanowski B.
Drugs, 2011, 71 (4) : 465 - 488
[43] Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2-and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial
Leung, Ting Fan
Liu, Anthony Pak-Yin
Lim, Fong Seng
Thollot, Franck
Oh, Helen May Lin
Lee, Bee Wah
Rombo, Lars
Tan, Ngiap Chuan
Rouzier, Roman
Friel, Damien
De Muynck, Benoit
De Simoni, Stephanie
Suryakiran, Pemmaraju
Hezareh, Marjan
Folschweiller, Nicolas
Thomas, Florence
Struyf, Frank
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (07) : 1689 - 1702
[44] A comprehensive natural history model of human papillomavirus (HPV) infection and cervical cancer: Potential impact of an HPV 16/18 vaccine
Goldie, S
Grima, D
Kohli, M
Weinstein, M
Wright, T
Franco, E
VALUE IN HEALTH, 2002, 5 (06) : 576 - 576
[45] The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK
Dasbach, E. J.
Insinga, R. P.
Elbasha, E. H.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2008, 115 (08) : 947 - 956
[46] Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine for the prevention of genital warts in males: Profile report
Garnock-Jones K.P.
Giuliano A.R.
Drugs in R&D, 2012, 12 (4) : 235 - 238
[47] Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls
Medina, Doris M. Rivera
Valencia, Alejandra
de Velasquez, Alet
Huang, Li-Min
Prymula, Roman
Garcia-Sicilia, Jose
Rombo, Lars
David, Marie Pierre P.
Descamps, Dominique
Hardt, Karin
Dubin, Gary
JOURNAL OF ADOLESCENT HEALTH, 2010, 46 (05) : 414 - 421
[48] Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine (vol 6, ofz486, 2019)
Chen, Jing
Gopala, Kusuma
Puthatta, Akarsh
Struyf, Frank
Rosillon, Dominique
OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (03):
[49] Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial
Lehtinen, Matti
Eriksson, Tiina
Apter, Dan
Hokkanen, Mari
Natunen, Kari
Paavonen, Jorma
Pukkala, Eero
Angelo, Maria-Genalin
Zima, Julia
David, Marie-Pierre
Datta, Sanjoy
Bi, Dan
Struyf, Frank
Dubin, Gary
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (12) : 3177 - 3185
[50] Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years (vol 25, pg 1197, 2010)
Kim, Young-Jae
Kim, Kyung-Tai
Kim, Jae-Hoon
Cha, Soon-Do
Kim, Jae Weon
Bae, Duk-Soo
Nam, Joo-Hyun
Ahn, Woong-Shick
Choi, Ho-Sun
Ng, Timothy
Bi, Dan
Ok, Jin-Ju
Descamps, Dominique
Bock, Hans L.
JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (12) : 1831 - 1831

← 1 2 3 4 5 →